Aventis To Pay $96M To End Medicaid Rebate Probe

By Melissa Lipman

Law360, New York (May 28, 2009, 12:00 AM ET) -- Aventis Pharmaceutical Inc. has agreed to pay $95.5 million to settle allegations that the drugmaker violated federal law by misreporting nasal spray prices in order to reduce its Medicaid rebate obligations.

The Sanofi-Aventis U.S. LLC subsidiary will give the U.S. government roughly $49 million; turn over $40 million to participating state Medicaid programs; and pay more than $6 million to public health service programs that overpaid for Aventis' Azmacort, Nasacort and Nasacort AQ, the U.S. Department of Justice announced Thursday.

The deal brings an end to...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles

Sections

Companies Mentioned

Government Agencies Mentioned